Franz Xaver Josef Escherich
Presidente presso OncoEthix SA
Provenienza dei contatti di primo grado di Franz Xaver Josef Escherich
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
OncoEthix SA
OncoEthix SA Pharmaceuticals: MajorHealth Technology OncoEthix SA operates as a clinical stage biotechnology company which develops cancer drugs. Its products include OTX008, OTX015, and OTX009. The company was founded by Esteban Cvitkovic, Jeanne Kay Noel, Yves Paternot, and Patrice Herait in March 2007 and is headquartered in Luzern, Switzerland.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
MSD Oncology Holdings Ltd.
MSD Oncology Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 1980, MSD Oncology Holdings Ltd. is a British business support services company that is part of Merck & Co., Inc. The company is based in Hoddesdon, UK.
4
| Subsidiary | Miscellaneous Commercial Services | 4 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Franz Xaver Josef Escherich tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Masters Business Admin | |
École Polytechnique Fédérale de Lausanne | College/University | Undergraduate Degree | |
Rhone Poulenc Rorer
Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | Chemicals: Specialty | Corporate Officer/Principal | |
Axovan AG
Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Miscellaneous Commercial Services | Chief Executive Officer | |
University of Michigan | College/University | Doctorate Degree | |
École Nationale Supérieure des Mines de Paris | College/University | Undergraduate Degree | |
Endeavour Vision SA
Endeavour Vision SA Investment ManagersFinance Endeavour Vision SA (EV) is an independent venture capital firm headquartered in Geneva. EV traces their origins back to 1989 through the convergence of the Vision Capital European team and the Swiss VC firm, Endeavour. EV was co-founded in 2000 by Sven Lingjaerde and Damien Tappy. The firm specializes in providing funding for entrepreneurs in life sciences, biotech, medtech, cleantech and information technology. EV operates in close cooperation with Genevest, an independent investment vehicle which has reached the divestment stage. Their investors in the funds they advise are industrial corporations, family offices, global institutional investors and business leaders in the technology and investment industry. | Investment Managers | Private Equity Analyst | |
ONCOVISTA INNOVATIVE THERAPIES, INC. | Pharmaceuticals: Major | General Counsel | |
Fondation Leenaards | Chairman | ||
Mestex AG
Mestex AG Pharmaceuticals: MajorHealth Technology Part of Grünenthal Pharma GmbH & Co. KG, Mestex AG is a Swiss pharmaceutical manufacturing company. The company is based in Basel, Switzerland. The CEO of the company is Olivier Valdenaire. Mestex was acquired by Grünenthal GmbH on April 12, 2021. | Pharmaceuticals: Major | Chief Executive Officer | |
ISREC Foundation
ISREC Foundation Miscellaneous Commercial ServicesCommercial Services ISREC Foundation provides resources to support translational cancer research projects. The non-profit company is based in Epalinges, Switzerland. | Miscellaneous Commercial Services | Chairman | |
Nelia & Amadeo Barletta Foundation | Investment Trusts/Mutual Funds | Chairman | |
Collaborative Medicinal Development LLC
Collaborative Medicinal Development LLC Pharmaceuticals: MajorHealth Technology Collaborative Medicinal Development LLC engages in the development of innovative therapies for neurodegenerative diseases and cancer. It offers CuATSM drug and clinical trials for ALS and Parkinson’s disease. The company is headquartered in Mill Valley, CA. | Pharmaceuticals: Major | Chief Operating Officer |
Statistiche
Distribuzione geografica
Svizzera | 10 |
Stati Uniti | 9 |
Francia | 6 |
Settori
Consumer Services | 7 |
Commercial Services | 5 |
Health Technology | 5 |
Producer Manufacturing | 2 |
Process Industries | 2 |
Posizioni
Director/Board Member | 7 |
Founder | 5 |
Corporate Officer/Principal | 4 |
Chairman | 4 |
Chief Executive Officer | 3 |
Contatti più connessi
- Borsa valori
- Insiders
- Franz Xaver Josef Escherich
- Connessioni Società